Effect of topical anti-inflammatory drugs on epithelial cell-induced eosinophil survival and GM-CSF secretion

European Respiratory Journal

Volumn 10, Issue 7, 1997, Pages 1489-1495

  Roca Ferrer, J ^a   Mullol, J ^a   Lopez, E ^a   Xaubet, A ^a   Pujols, L ^a   Fernandez J C ^a   Picado, C ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Beclamethasone dipropionate; Budesonide; Eosinophils; Epithelial cells; Fluticasone propionate; Nedocromil sodium

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; FLUTICASONE PROPIONATE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; NEDOCROMIL SODIUM;

ADOLESCENT; ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL INTERACTION; CELL SURVIVAL; CLINICAL ARTICLE; DRUG MECHANISM; DRUG POTENCY; EOSINOPHILIA; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; MALE; NOSE SURGERY; PRIORITY JOURNAL; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADULT; ANTI-INFLAMMATORY AGENTS; CELL SURVIVAL; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; EOSINOPHILS; EPITHELIAL CELLS; FEMALE; GLUCOCORTICOIDS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; MALE; NASAL MUCOSA;

EID: 0030878224     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.97.10071489     Document Type: Article

References (31)

1. Iliopoulos O, Proud D, Adkinson NF, et al. Relationship between the early, late and rechallenge reaction to nasal challenge with antigen: observations on the role of inflammatory mediators and cells. J Allergy Clin Immunol 1990; 86: 851-861.
2. Bousquet JB, Chanez P, Lacoste JY, et al. Eosinophilic inflammation in asthma. N Engl J Med 1990; 323: 1033-1039.
3. Djukanovic R, Wilson JW, Britten KM, et al. The effects of inhaled beclomethasone (BDP) on inflammatory cells in the asthmatic airway. J Allergy Clin Immunol 1991; 87(2): 172.
4. Stern M, Meagher L, Savill J, Haslett C. Apoptosis in human eosinophils. J Immunol 1992; 148: 3543-3549.
5. Corrigan CJ, Bungre JK, Assoufi B, Cooper AE, Seddon H, Kay AB. Glucocorticoid-resistant asthma: T-lymphocyte steroid metabolism and sensitivity to glucocorticoids and immunosuppressive agents. Eur Respir J 1996; 9: 2077-2086.
6. de Jong JW, Postma DS, de Monchy JGR, Koëter GH. A review of nedocromil sodium in asthma therapy. Eur Respir Rev 1993; 3: 511-519.
7. Youngchaiyud P, Lee TB. Effect of nedocromil sodium on the immediate response to antigen challenge in asthmatic patients. Clin Allergy 1986; 16: 129-134.
8. Aalbers R, Kauffman HF, Groen H, Koëter GH, de Monchy JGR. The effect of nedocromil sodium on the early and late reaction and allergen-induced bronchial hyperresponsiveness. J Allergy Clin Immunol 1991; 87: 993-1001.
9. Moqbel R, Cromwell O, Walsh GM, Wardlaw AJ, Kurlak L, Kay AB. Effects of nedocromil sodium (Tilade®) on the activation of human eosinophils and neutrophils and the release of histamine from mast cells. Allergy 1988; 43: 268-276.
10. Moqbel R, Walsh GM, Kay AB. Inhibition of human granulocyte activation by nedocromil sodium. Eur J Respir Dis 1986; 69 (Suppl. 147): 227-229.
11. Leung KBP, Flint KC, Brostoff J, Hudspith BN, Johnson N, Pearce FL. A comparison of nedocromil sodium and sodium cromoglycate on human lung mast cells obtained by bronchoalveolar lavage and by dispersion of lung fragments. Eur J Respir Dis 1986; 69 (Suppl. 147): 223-226.
12. Bruijnzeel PLB, Warringa RAJ, Kok PTM, Kreukniet J. Inhibition of neutrophil- and eosinophil-induced chemotaxis by nedocromil sodium and sodium cromoglycate. Br J Pharmacol 1990; 99: 798-802.
13. Spry CJF, Kumaraswami V, Tai PC. The effect of nedocromil sodium on secretion from human eosinophils. Eur J Respir Dis 1986: 69 (Suppl. 147): 241-243.
14. Bruijnzeel PLB, Hamelink ML, Kok PTM, Kreukniet J. Nedocromil sodium inhibits the A23187 and opsonized zymosan-induced leukotriene formation by human eosinophils but not by human neutrophils. Br J Pharmacol 1989; 96: 631-636.
15. Marini M, Soloperto M, Zheng Y, Mezzetti M, Mattoli S. Protective effect of nedocromil sodium on the IL-1-induced release of GM-CSF from cultured human bronchial epithelial cells. Pulm Pharmacol 1992; 5: 61-65.
16. Vittori E, Sciaacca F, Colotta F, Mantovani A, Mattoli S. Protective effect of nedocromil sodium on the interleukin-1-induced production of interleukin-8 in human bronchial epithelial cells. J Allergy Clin Immunol 1992; 90: 76-84.
17. Xaubet A, Mullol J, López E, et al. Comparison of the role of nasal polyp and normal nasal mucosal epithelial cells on in vitro eosinophil survival: mediation by GM-CSF and inhibition by dexamethasone. Clin Exp Allergy 1994; 24: 307-317.
18. Mullol J, Xaubet A, López E, Roca-Ferrer J, Picado C. Comparative study of the effects of different glucocorticosteroids on eosinophil survival primed by cultured epithelial cell supernatants obtained from nasal mucosa and nasal polyps. Thorax 1995; 50: 270-274.
19. Cox G, Ohtoshi T, Vancheri C, et al. Promotion of eosinophil survival by human bronchial epithelial cells and its modulation by steroids. Am J Respir Cell Mol Biol 1991; 4: 525-531.
20. Brattsand R, Selroos O. Current drugs for respiratory diseases. Glucocorticoids. In: Page CP, Metzger WJ, eds. Drugs and the Lung. New York, Raven Press, 1994: pp. 101-220.
21. Högger P, Rohdewald P. Binding kinetics of fluticasone propionate to the human glucocorticoid receptor. Steroids 1994; 59: 597-602.
22. Phillipps GH. Structure-activity relationships of topically active steroids: the selection of fluticasone propionate. Respir Med 1990; 84 (Suppl. A): 19-23.
23. Mullol J, Xaubet A, Gaya A, et al. Cytokine gene expression and release from epithelial cells: a comparison study between healthy nasal mucosa and nasal polyps. Clin Exp Allergy 1995; 25: 607-615.
24. Barnes NC, Marone GU, Di Maria S, Visser S, Utama I, Payne SL. A comparison of fluticasone dipropionate, 1 mg daily, with beclomethasone dipropionate, 2 mg daily, in the treatment of severe asthma. Eur Respir J 1993; 6: 877-884.
25. -1, in mild and moderate asthma. Arch Dis Child 1993; 69: 206-211.
26. Ratner PH, Paull BR, Findlay SR, et al. Fluticasone propionate given once daily is as effective for seasonal allergic rhinitis as beclomethasone dipropionate given twice daily. J Allergy Clin Immunol 1992; 90: 285-291.
27. Ayres JG, Bateman ED, Lundback B, Harris TAJ. High-dose fluticasone propionate, 1 mg daily, versus fluticasone propionate, 2 mg daily, or budesonide, 1.6 mg daily, in patients with chronic severe asthma. Eur Respir J 1995; 8: 579-586.
28. Svendsen UG, Frolund L, Madsen F, Nielsen NH. A comparison of the effects of nedocromil sodium and beclomethasone dipropionate on pulmonary function, symptoms and bronchial responsiveness in patients with asthma. J Allergy Clin Immunol 1989; 84: 224-231.
29. Boe J, Rosenhall L, Alton M. Comparison of doseresponse effects of inhaled beclomethasone dipropionate and budesonide in the management of asthma. Allergy 1989; 44: 349-355.
30. Svendsen UG, Frolund L, Heinig JH, Madsen F, Nielsen NH, Weeke B. High-dose inhaled steroids in the management of asthma: a comparison of the effects of budesonide and beclomethasone dipropionate on pulmonary function, symptoms, bronchial responsiveness and adrenal function. Allergy 1992; 47: 174-180.
31. Würthwein G, Rohdewald P. Activation of beclomethasone dipropionate by hydrolysis to beclomethasone-17-monopropionate. Biopharm Drug Dispos 1990; 11: 381-394.